Research programme: targeted MRI contrast agents - Guerbet/ImaRx TherapeuticsAlternative Names: Targeted MRI contrast agents research programme - Guerbet/ImaRx Therapeutics
Latest Information Update: 14 May 2007
At a glance
- Originator Guerbet; ImaRx Therapeutics
- Class Contrast media
- Mechanism of Action Magnetic resonance imaging enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 15 Dec 2004 Preclinical trials in Cancer diagnosis in USA (Injection)